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Fibrinolytic therapy is an alternative to urgent reoper-
ation for patients with St. Jude prosthetic valve throm-
bosis, but requires an accurate mefhod for repeated as-
sessment of prosthetic function. Since the St. Jude valve
is not well visualized by conventional cinefluoroscopy,
digital subtraction techniques were developed that im-
proved visualization of the valve and allowed assessment
of leaflet separation and velocuy. A 74 year old woman
with prosthetic valve thrombosis 5 years after St. Jude
aortic valve placement had an opening angle of 58° (nor-
mal range 10 to 13; n = 8) with a maximal opening
velocity of 1.37°/ms (normal range 2.46 to 2.93). The
closing angle was 125° (normal range 120 to 127) with
a maximal closing velocity of 1.38°/ms (normal range
2.24 to 3.60). The patient received 250,000 U'of strep-
tokinase intravenously, then 100,000 Vlh for 72 hours.
Improvement in auscultatory findings occurred at 12
Thrombus formation is a potentially life-threatening com-
plication of cardiac valve replacement and has been reported
to occur with all commonly used mechanical prostheses
(1-10). The incidence of thrombotic obstruction may be as
high as 8.1 % per patient-year if anticoagulation is omitted
or discontinued after valve replacement (4). Traditional ther-
apy has been emergent reoperation (11), but in this setting,
the operative mortality rate is 40% or greater (4-15). Re-
current thrombosis may occur despite reoperation (13,14).
Fibrinolytic therapy is an alternative approach that may
obviate the need for emergent reoperation in selected pa-
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hours; repeat digital cinefluoroscopy showed an opening
angle of 20° with a maximal velocity of 2.77°/ms, and a
closing angle of 126° with a maximal velocity of 1.91°/ms.
Digital cinefluoroscopy 4 weeks after discharge on war-
farin and dipyridamole therapy was unchanged. There
have been n~ thromboembolic complications after 6
months of follow-up.
Thus, digital cinefluoroscopy is a new noninvasive
technique that permits accurate measurement of normal
and abnormal St. Jude h~afle~ function. Intravenous
streptokinase dissolution of prosthetic valve thrombosis
under digital clnefluoroscople guidance may be an ac-
ceptable alternative to emergency reoperation. The fre-
quency and significance of residual subclinical leaflet
dysfunction after fibrinolytic therapy and the indications
for elective reoperatiqn' require further evaluation.
(J Am Coil CardioI1985;5:1244-9)
tients (12-24). Such an approach ideally requires accurate
and repeated measurement of prosthetic leaflet motion to
track the progress of thrombus dissolution. Cinefluoroscopy
has been used successfully for this purpose with radiopaque
prostheses (14,15). However, the St. Jude valve is not well
visualized by conventional cinefluoroscopy.
This study describes the use of a new radiographic tech-
nique, digital cinefluoroscopy, for measuring leaflet motion
before, during and after fibrinolytic therapy in a patient with
a thrombosed St. Jude aortic valve and compares the results
with those obtained from eight patients with a normal St.
Jude prosthesis.
Methods
Image acquisltion, Computer-enhanced, digitally sub-
tracted, videodensitometric fluoroscopy ("digital cinefluo-
roscopy") was performed with a Philips Maximus MIOO
cineangiographic C-ann X-ray generator with an Eimac one
million heat unit X-ray tube and a Thompson image inten-
sifier. A tangential view of the St. Jude valve (25,26) was
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required for optimal leaflet visualization. Because of indi-
vidual variability in valve position and orientation, careful
patient positioning was mandatory and frequently necessi-
tated the use of caudocranial angulation. Imaging was com-
pleted within 15 minutes after arrival in the cardiac cathe-
terization laboratory. Images were acquired at a rate of 30
frames/s, utilizing a pulse width of 5 ms at energy levels
of 75 to 100 kVp and 200 to 300 rnA, and were stored in
512 X 512 x 8 bit matrices after analog to digital con-
version and logarithmic transformation. The stored images
were processed with an AOAC OPS-4100 computer for
mask subtraction (I to 2 seconds summed mask), noise
filtration, edge enhancement and magnification. Resultant
processed images in a patient with a normal St. Jude valve
prosthesis are shown in Figure 1.
Analysis of leaflet separation and velocity. Leaflet po-
sition and angular separation (in degrees) were determined
from frame by frame analysis of a single cardiac cycle (Fig.
2). Leaflet velocity (degrees per ms) was calculated as the
difference in angular separation between successive frames,
divided by the time interval (33.3 ms at 30 frames/s). Soft-
Figure 1. Digital cinefluoroscopic images of normal St. Jude aor-
tic valve. Line of view parallel to outflow tract (A) and oblique
off-axis view (B) demonstrate prosthetic ring, orifice and leaflets
(open position). Views in plane of prosthetic ring demonstrate
leaflets (closed position) in nontangential (C) and tangential (D)
projections.
Results
Control patients (Table 1). Eight patients who had
undergone aortic St. Jude valve replacement within the pre-
vious year were randomly selected from our cardiac surgical
data base. All eight patients were in New York Heart As-
sociation functional class I, had normal prosthetic auscul-
tatory findings and consented to undergo digital cinefluo-
roscopic examination.
Mean leaflet separation (± SO) in the open position was
11 ± 1° (normal range 10 to 13). In the closed position,
leaflet separation was 124 ± 2° (normal range 120 to 127).
ware developed by one of us (J. M.P.) allowed automated
detection of leaflet position and computation of leaflet angles
and velocities. The maximal leaflet velocity theoretically
detectable was 3.600/ms, determined from the maximal an-
gular excursion (130° leaflet separation in the closed posi-
tion, 10° in the open position, net = 120°) divided by the
shortest time interval (one frame, 33.3 ms). The number of
frames per cardiac cycle was dependent on the heart rate
(approximately 45 to 90 beats/min) and ranged from 20 (at
a heart rate of 90 beats/min) to 40 frames/cycle (at a heart
rate of 45 beats/min).
Statistical analysis. Values of continuous variables are
represented as mean ± standard deviation.
Figure 2. Schematic representation of leaflet separation in the
open (A) and closed (B) position from the tangential projections.
The manufacturer's specified leaflet angle of separation (arrows)
in the open position is 10° and in the closed position is 120° (19
to 25 mm valves).
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Table l. Leaflet Separation and Velocity in Eight Control Patients With an Aortic SI. Jude Valve
Valve Size Leaflet Separat ion (degrees) Maximal Velocity (degreeslms) Heart Rate
Case (mm) Opened Closed Opening Closing (min - I)
I 19 13 126 2.72 3.06 90
2 19 11 124 2.63 3.59 74
3 2 1 10 126 2.90 2.24 7 1
4 2 1 10 120 2.81 3.37 57
5 23 10 124 2.46 3.60 48
6 23 10 122 2.73 2.75 56
7 25 11 125 2.55 3.30 62
8 25 12 127 2.93 3.08 72
Mean ± SD II ± I 124 ± 2 2.72 ± 0.16 3.12 ± 0.46
Range 10 to 13 120 to 127 2.46 to 2.93 2.24 to 3.60
The maximal opening velocity was 2.72 ± 0. 16°/ms and
varied over a fairly narrow range (2.46 to 2.93). The max-
imal closing velocity was greater (3.12 ± 0.46°/ms), but
varied over a wider range (2.24 to 3.60) and approached
the theoretical upper limit of 3.600/ms in two patients (Cases
2 and 5) .
Case report: thrombosed valve (Table 2). In 1979, a
74 year old woman underwent aortic valve replacement with
a 21 mm St. Jude valve prosthesis and saphenous vein
bypass grafting to the left anterior descending and circum-
flex coronary arteries . Postoperatively, she was treated with
warfarin sodium (Coumadin) for anticoagulation, and on
follow-up she was free of symptoms with moderate activity .
Five years later (at 79 years of age) after a decrease in her
Coumadin dosage, she developed diminished exercise tol-
erance and exertional syncope over a 10 day period.
On physical examination (blood pressure 150/90 mm Hg,
pulse 58/min), the carotid impulse had a slowed upstroke
for her age and a normal volume ; there was no jugular
venous distension. The prosthetic valve opening sound was
absent. The closing sound was present, but had a muffled
quality . A grade 3/6 harsh, crescendo-decrescendo, mid-
systolic murmur was noted at the left sternal edge and aortic
area , with radiation to both carotid arteries . The lungs were
clear to auscultation. A clinical diagnosis of suspected pros-
thetic valve thrombosis was made, and the patient was ad-
mitted to the hospital.
On admission, the prothrombin time was 12.9 seconds,
with a contro l value of 10.6 seconds (therapeutic range 20
to 25). M-mode and two-dimensional echocardiography were
attempted , but did not provide adequate visualization of the
prosthetic valve or its leaflets. Digital cinefluoroscopy (Fig .
3A) was distinctly abnormal : leaflet separation during sys-
tole was 58° (normal range 10 to 13) and during diastole
was 125° (normal range 120 to 127). The maximal opening
velocity was decreased at 1.37°/ms (normal range 2.46 to
2.93) and the closing velocity at 1.38°/ms (norma l range
2.24 to 3.60) . Because of the patient's advanced age, prior
valve replacement and coronary bypass grafting, the risk of
reoperation was deemed too high. Fibrinolytic therapy under
guidance of digital cinefluoroscopy with surgical standby
was thought to be a safer alternative.
Intravenous streptokinase (250 ,000 U) was administered
over 30 minutes, followed by a constant infusion of 100,000
Uzh for 72 hours. At 12 hours, physica l examination re-
vealed reappearance of the opening prosthetic click and a
louder closing sound; the mid-systolic murmur decreased in
intensity to grade 2/6. Digital cinefluoroscopy demonstrated
improveme nt in systolic leaflet separation to 20°, normal-
ization of the opening velocity and an increase in closing
velocity (Fig. 3B). No further improvement in these vari-
ables occurred at 36 or 72 hours. The patient was heparin-
ized after discontinuation of streptokinase therapy , and was
discharged taking warfarin and dipyridamole (75 mg three
times daily). Prothrombin times have been maintained at 2
to 2 '12 times control level.
Table 2. Leaflet Separation and Velocity in a Patient With Thrombosed Aortic
SI. Jude Valve (21 mm)
Leaflet Separation Maximal Velocity
(degrees ) (degreeslms)
Heart Rate
Time Opened Closed Opening Closing (min - I)
Before streptokinase 58 125 1.37 1.38 72
12 hours after streptokinase 20 126 2.77 1.91 64
4 weeks after discharge 22 126 2.52 1.99 55
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figure 3. Digital cinefluoroscopy of thrombosed aortic St. Jude
valve in tangential projection before (A) and 12 hours after (B)
administration of intravenous streptokinase. The upper panels
demonstrate the leaflets in the maximally open position and the
lower panels demonstrate the leaflets in the closed position. Note
the marked improvement in leaflet separation in the open position
after streptokinase therapy,
Four weeks after discharge. repeat digital cinefluoros-
copy demonstrated variables that were very similar to those
obtained 12 hours after streptokinase therapy (Table 2).
After 6 months of follow-up, there have been no throm-
boembolic complications. The patient has returned to her
normal activities, and has remained free of her previous
symptoms.
Discussion
Prosthetic valve thrombosis. Postmortem studies of
patients dying late after operation (27,f8) have identified
thrombus in 30 to 69% of mechanical heart valves. These
thrombi were usually small and clinically concealed, but in
30% of patients there was resultant prosthetic dysfunction,
and in 20% systemic embolization had occurred (27). The
risk of thrombus formation and subsequent embolization has
been reduced by careful design of prostheses (to avoid areas
of stasis and thrombogenic component interfaces) and by
the use of pyrolytic carbon to coat valve surfaces (28).
Despite these improvements, thromboembolic complica-
tions have not been completely eliminated. Proper antico-
agulation continues to be recommended for all patients with
mechanical valves (2) including the St. Jude valve (29-33).
Inadequate anticoagulation was the probable cause of pros-
thetic valve thrombosis in our patient. Other factors known
to increase thromboembolic risk (2), such as atrial fibril-
lation, a large left atrium, previous history of recurrent
emboli, left atrial thrombus at prior operation or multiple
valve replacement, were not present.
Dlagnostic evaluation. The clinical presentation of valve
thrombosis is usually that of sudden onset of pulmonary
edema and low cardiac output (6-8,14,15), which may be
accompanied by cerebral, myocardial or systemic emboli-
zation. Occasionally, the presentation is less catastrophic,
with a gradual onset of heart failure or exertional dyspnea
(15), as in the present case. Accurate and prompt diagnosis
of prosthetic thrombosis is essential, because the prognosis
in untreated patients is poor.
Auscultatory and phonocardiographicfindings in patients
with a notmally functioning St. Jude valve are variable
(34-40). A prosthetic opening sound has not been consist-
ently detected; in the largest reported patient series (39),
only 15%of aortic valve prostheses had a detectable opening
sound. A closing sound is uniformly present, and is usually
of a high-pitched quality. A mid-systolic murmur occurs in
70% of normally functioning aortic St. Jude valves (3~).
Both the opening and closing sounds may be preserved with
prosthetic valve thrombosis, especially when only one leaf-
let is affected (34,40). Thus, the findings of an absent pros-
thetic opening sound, a preserved closing sound and an
aortic systolic murmur in the present case were consistent
with, but not diagnostic for, prosthetic valve thrombosis.
Echocardiography is limited by the inability, as in our
case, to visualize both leaflets of the St. Jude valve, and to
obtain views in the proper orientation given the variability
of positioning when the valve is implanted (34-39). Tech-
nically adequate studies sufficient for assessment of bileaflet
function can be obtained in only 24% of prostheses in the
aortic position (39). Quantitative measures of prosthetic
function (leaflet separation, opening and closing velocities)
have demonstrated wide variability (34-36,38).
Conventional radiographic visibility ofthe St. Jude valve
is poor (25,26). Despite impregnation with 5 to 10% tung-
sten, the leaflets are not visualized well cinefluoroscopically
except in the tangential view, and the valve ring is usually
not visualized at all. Digital subtraction techniques in our
study allowed excellent visualization of the valve leaflets in
all patients; in addition, the leaflets were well visualized in
nontangential views, and the valve ring could be seen easily
(Fig. I). Quantitation of leaflet function was obtained in the
tangential view (Fig. 1D and 2) to standardize the mea-
surements and because of differences in orientation of the
valve from patient to patient. The variability in measurement
of leaflet separation and angular velocity was small (standard
deviation < 15% of the mean) (Table 1). Leaflet function
in the thrombosed valve was strikingly abnormal, with leaf-
let separation in the open position and maximal opening and
closing velocities clearly outside the normal range (Table
2).
Fibrinolytic therapy. A total of 40 patients, as reported
in previous studies (12-24), have been treated with strep-
tokinase or urokinase for prosthetic valve thrombosis. Al-
though streptokinase is usually reserved for prosthetic
thrombosis of recent onset (:514 days), a chronically throm-
bosed prosthetic valve (6 months' duration) has been suc-
cessfully treated with this agent (17).
1248 CZER ET AL.
ST. JUDE VALVE THROMBOSIS
JACC Vol. 5, No.5
May 1985:1244-9
Results of the two largest patient series (a total of 24
cases) (14,15) demonstrate complete success in 16 cases
(67%) and improvement but incomplete resolution of phono-
cardiographic, echocardiographic or cinefluoroscopic signs
in 4 (17%), allowing for elective reoperation that was suc-
cessful in 3 of the 4 cases. Fibrinolytic therapy was con-
sidered a failure in four cases (17%) requiring emergent
reoperation (successful in two of the four). Three deaths
(12.5%) occurred before or during reoperation. Embolic
complications, all transient and nonfatal, occurred in three
(12.5%) and two patients had nonfatal bleeding complica-
tions (hemopericardium in one, uterine bleeding in one).
One recurrence was treated successfully with fibrinolytic
therapy.
Potential advantages of thrombolytic therapy include the
avoidance of reoperation in most patients, a reduction in
the number of reoperations performed on an emergency
basis and the opportunity to reoperate on an elective basis
in the remaining patients. Overall mortality with this ap-
proach appears to be reduced (14,15).
Fibrinolytic treatment (14,15,41-43) consists of intra-
venous streptokinase at a loading dose of 250,000 to 500,000
IV over 30 to 40 minutes, followed by 100,000 IV/h for
12 to 96 hours (14,41-43), or 150,000 IV/h for 10 hours
(15) or urokinase, 4400 IV/kg per h for 12 hours after a
loading dose of 4400 Il.l/kg over 10 minutes. Confirmation
of thrombolytic effect is obtained by measurement of a
shortened euglobulin clot lysis time, presence of fibrin deg-
radation products or a prolonged thrombin time. After dis-
continuation of fibrinolytic therapy and the partial throm-
boplastin time has decreased to twice normal, heparin infusion
is begun without a loading dose and maintained for 5 to 10
days. Heparin therapy is followed by long-term anticoag-
ulation therapy with warfarin.
Use of digital cinefluoroscopy in evaluating efficacy
of fibrinolytic therapy. The use of fibrinolytic therapy for
prosthetic valve thrombosis demands the verification ofther-
apeutic efficacy by a noninvasive method that can be per-
formed on repeated occasions over time. The excellent vi-
sualization of the St. Jude valve obtained in all patients in
this study suggests that this approach is well suited to such
an application.
End points of fibrinolytic therapy have been relief of
symptoms and normalization of phonocardiographic, echo-
cardiographic or cineangiographic abnormalities. In the ma-
jority of reported cases (12-24), these end points were reached
within 12 to 24 hours. In this study, all of the improvement
in valve function occurred within the first 12 hours of fi-
brinolytic therapy. Assessment of efficacy by auscultation
(return of opening prosthetic click, presence of closing click)
or by qualitative cinefluoroscopy (valve opening and closing
grossly normal) would suggest that the fibrinolytic therapy
was successful. However, continued minor abnormalities
detected by digital cinefluoroscopy suggest that the success
was only partial. Given the patient's excellent clinical re-
sponse and lack of thromboembolic complications while
receiving warfarin and dipyridamole therapy, the risk of
continued anticoagulation therapy with close follow-up by
digital cinefluoroscopy has been judged to be low compared
with that of reoperation.
Shortcomings of digital cinefluoroscopy for evaluation
of St. Jude leaflet function and prosthetic valve throm-
bosis. At its present stage of development, digital cine-
fluoroscopy has not visualized thrombus formation directly;
rather, the presence of prosthetic valve thrombus is inferred
from the finding of abnormal leaflet function. Restriction
of aortic leaflet function may not result solely from thrombus
formation, but may potentially occur with tissue over-
growth, paravalvular leak or possibly ventricular septal hy-
pertrophy (6,8,44-46). Therefore, caution is advised in the
interpretation of restricted St. Jude leaflet motion. Incom-
plete resolution of leaflet dysfunction after streptokinase
therapy is usually an indication for reoperation (14,15). The
proportion of incomplete responses that are due to residual
thrombotic obstruction versus tissue overgrowth or other
factors is unknown and requires further investigation. Pan-
nus formation may represent organization of thrombus, could
account for incomplete resolution of leaflet dysfunction and
thus may be related to variable age of thrombus formation.
Maximal valve closing velocity approached the theoretic
upper limit of detection in two of eight control patients.
Since this upper limit is determined by the rate of image
acquisition, digital cinefluoroscopy of the St. Jude valve
should probably be performed with a frame speed faster
than 30 frames/so The optimal frame speed is not known,
but 50 to 60 frames/s should suffice.
Computerized equipment needed to perform digital cine- .
fluoroscopy is expensive and is not widely available at pres-
ent. Avoidance of the expense of reoperation in most pa-
tients given streptokinase for prosthetic thrombosis may justify
the use of this technique at centers with a large number of
referred patients who have had previous valve replacement.
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